Key Takeaway: Voyager Therapeutics has reported its third quarter 2023 financial results, highlighting the initiation of GLP toxicology studies for its VY-TAU01 anti-tau antibody aimed at Alzheimer's disease. The company anticipates filing an Investigational New Drug (IND) application in the first half of 2024. Additionally, the SOD1 ALS gene therapy program is on track for development candidate selection by the end of the year.
Price reaction · baseline $6.49 (2023-11-06 close) · hit after-hours · clean, no other VYGR news in the window
day 0 close · peak
+5.1%
day 1
+4.9%
day 3
-2.2%
Market Sentiment Analysis
POSITIVE FACTORS
Initiation of GLP toxicology studies for VY-TAU01 antibody.
Anticipated IND filing for Alzheimer's treatment in 1H 2024.
SOD1 ALS gene therapy program on track for candidate selection.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
3%
average across 2 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
VP4896
Phase 3 · Alzheimer's Disease
Full Press Release Details
– GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing – – SOD1 ALS gene therapy program on track for development candidate selection by end of year – – Conference call at 4:30 p.m. ET today – LEXINGTON, Mass. , Nov.
Frequently Asked Questions
What studies were initiated for VY-TAU01?
GLP toxicology studies were initiated for the VY-TAU01 anti-tau antibody.
When is the anticipated IND filing for VY-TAU01?
The IND filing for VY-TAU01 is anticipated in the first half of 2024.
What is the status of the SOD1 ALS program?
The SOD1 ALS gene therapy program is on track for candidate selection by year-end.
When is the conference call scheduled?
The conference call is scheduled for 4:30 p.m. ET today.